UBE2C:前列腺癌患者的潜在治疗标和预后生物标志物
Shan Li1,2, Yang Liu3, Xun Wu1,2
1The First School of Clinical Medicine, Lanzhou University, Lanzhou City, Gansu Province, 730000, China.
Functional & integrative genomics
|July 25, 2025
概括
乌比奎丁结合酶E2C (UBE2C) 促进前列腺癌 (PRAD) 的进展. 抑制UBE2C抑制了PRAD细胞生长,迁移和入侵,这表明UBE2C是固体瘤的潜在预后标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 乌比奎丁结合酶E2C (UBE2C) 与各种癌症有关.
- 在前列腺癌 (PRAD) 中UBE2C的特定作用和预后价值尚未明确.
研究的目的:
- 研究UBE2C在前列腺癌中的表达,预后意义和功能作用.
- 评估UBE2C作为PRAD的潜在诊断和预后生物标志物.
主要方法:
- 使用TCGA,GEO,cBioPortal和COSMIC数据库进行表达和突变分析.
- 采用了细胞增殖 (CCK8,殖民地形成,Edu染色),迁移/入侵试验,细胞循环,细胞亡分析和异种移植模型.
- 进行了功能丰富分析,以了解UBE2C的生物功能.
主要成果:
- UBE2C表达水平与PRAD进展相关.
- 抑制UBE2C显著抑制PRAD细胞的增殖,迁移,入侵和异种移植瘤的生长.
- UBE2C倒置改变了PRAD细胞的细胞周期分布,并诱导了PRAD细胞的亡.
结论:
- UBE2C在前列腺癌的发展和进展中起着至关重要的作用.
- UBE2C作为一种潜在的新型分子标志物,用于评估固体瘤的预后,包括PRAD.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:38Mitogens and the Cell Cycle
6.9K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K